Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy
- 145 Downloads
Background The objective of this study was to assess the safety, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), pharmacokinetics, and anti-tumor efficacy of CKD-581, a novel pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma (MM) refractory to standard therapy. Methods In this phase I study, CKD-581 was intravenously administered on days 1, 8, and 15 of a 28-day cycle. A standard 3 + 3 cohort design was used to determine the MTD. Acetylated histones H3 and H4 in peripheral blood mononuclear cells were measured for pharmacodynamic assessment in a subpopulation of patients. Results Thirty-nine patients were treated with CKD-581 at 9 dose levels from 10 mg/m2 to 210 mg/m2. The DLTs were grade 3 neutropenia that delayed the treatment for >2 weeks (one patient at a dose of 50 mg/m2) and grade 4 thrombocytopenia (two patients at a dose of 210 mg/m2). The MTD of CKD-581 was 160 mg/m2. The most common grade 3/4 treatment-related adverse events were thrombocytopenia (n = 5, 12.8%) and neutropenia (n = 2, 5.1%). The peak concentration and area under the curve values for CKD-581 increased in proportion to the dose, indicating linear pharmacokinetics. A partial response was observed in 2 patients (5.6%), and stable disease was observed in 16 (44.4%) patients. In the pharmacodynamic evaluation, acetylation of H3 and H4 was observed at all doses of ≥50 mg/m2. Conclusion CKD-581 was well tolerated by the patients with lymphoma or MM refractory to standard therapy. It exhibited dose-proportional pharmacokinetics and modest anti-tumor efficacy.
KeywordsLymphoma Multiple myeloma Histone deacetylase inhibitor Pharmacokinetics Pharmacodynamics
This study was supported by Chong Kun Dang Pharm.
Compliance with ethical standards
Conflict of interest
The authors have no conflicts of interest to declare.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consents were obtained from all participants included in the study.
- 1.Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon. Available from: http://globocan.iarc.fr, Accessed 13 Oct 2017
- 4.Lee C, Ahn KS, Jung WJ, Koh Y, Kim HJ, Lee HJ et al (2014) CKD-581, a novel histone deacetylase inhibitor, synergistically enhances Bortezomib cytotoxicity in multiple myeloma cells [abstract]. Annual Meeting of the American Association for Cancer Research 74(19 Supplement):Abstract nr 1695Google Scholar
- 5.Kim MJ, Lee CS, Lee DH, Yang HM, Lim IT, Bae DI, et al (2011) Activity of CKD-581, histone deacetylase inhibitor, in cutaneous T-cell lymphoma models [Poster abstract]. Eur J Cancer. Sep;47:S642: Poster nr 9208Google Scholar
- 6.Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials (2010) J Natl Cancer Inst. 20;101(10):708–702Google Scholar
- 10.O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 10;33(23):2492–2499Google Scholar
- 12.Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A et al (2013) A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res 19(15):4262–4272CrossRefPubMedGoogle Scholar